Topic Highlight
Copyright ©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Apr 14, 2014; 20(14): 3835-3846
Published online Apr 14, 2014. doi: 10.3748/wjg.v20.i14.3835
Chemopreventive drugs: Mechanisms via inhibition of cancer stem cells in colorectal cancer
Tae Il Kim
Tae Il Kim, Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul 120-752, South Korea
Author contributions: Kim TI collected data and references, and designed and wrote the paper.
Correspondence to: Tae Il Kim, MD, PhD, Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, 50 Yonseiro, Seodaemun-gu, Seoul 120-752, South Korea. taeilkim@yuhs.ac
Telephone: +82-2-22281965 Fax: +82-2-3936884
Received: October 2, 2013
Revised: November 27, 2013
Accepted: January 3, 2014
Published online: April 14, 2014
Core Tip

Core tip: To develop optimal chemopreventive agents, we need to target cells and pathways that are essential and critical to carcinogenesis: early tumorigenic changes of stem cells and signals for dedifferentiation may be good targets for chemoprevention. Major chemopreventive drugs, such as non-steroidal anti-inflammatory drugs, statins, proliferator-activated receptor γ agonists and metformin, have cancer stem cell (CSC)-suppressing effects via regulation of stem cell-regulating pathways, stem cell niche in the tumor microenvironment, and altered tumor metabolism. These stem cell-related steps in tumorigenesis could be critical targets for chemoprevention and CSC-targeted adjunctive treatment of colorectal cancer.